US4178360A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiolabelled rubella virus and method
Assignee: Hoffmann La Roche Inc
•
Filing: 1978-03-15
•
Granted: 1979-12-11
•
Expires: 1998-03-15
Abstract
Abstract A novel labelled antigen consisting of 125I-rubella virus and its use in a radioimmunoassay for rubella virus specific antibodies in human serum is disclosed.
Inventors
- 👤 Roy Cleeland
- 👤 Joanne Durkin
- 👤 Michael J. Kramer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 10:35
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56983; Y; Y10; Y10S; Y10S436/00; Y10S436/811
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
3 words
125 I-rubella virus.
Claim 2
Dependent Claim
3 words
125 I-rubella virus.
Claim 3
Dependent Claim
132 words
In an immunoassay for determining the presence of rubella virus specific antibodies in human serum which comprises the steps of: A. Providing a reaction mixture comprising a buffered aqueous medium; human serum to be assayed; antigen derived from rubella virus and a second antibody specific to human IgG; B. Incubating said reaction mixture to form an antigen-antibody-second antibody conjugate when said rubella virus specific antibody is present in said serum sample, said conjugate bearing a detectable label; and C. Determining the level of said label as a measure of the presence of said antigen-antibody-second antibody conjugate and correlating said level against a standard curve to determine whether positive levels of said rubella virus specific antibody were present in said serum sample; the improvement which comprises utilizing 125 I-rubella virus as the antigen.
Claim 4
Dependent Claim
132 words
In an immunoassay for determining the presence of rubella virus specific antibodies in human serum which comprises the steps of: A. Providing a reaction mixture comprising a buffered aqueous medium; human serum to be assayed; antigen derived from rubella virus and a second antibody specific to human IgG; B. Incubating said reaction mixture to form an antigen-antibody-second antibody conjugate when said rubella virus specific antibody is present in said serum sample, said conjugate bearing a detectable label; and C. Determining the level of said label as a measure of the presence of said antigen-antibody-second antibody conjugate and correlating said level against a standard curve to determine whether positive levels of said rubella virus specific antibody were present in said serum sample; the improvement which comprises utilizing 125 I-rubella virus as the antigen.
Claim 5
Dependent Claim
14 words
The improved immunoassay of claim 2 wherein said second antibody is goat anti-human IgG.
Claim 6
Dependent Claim
18 words
The improved immunoassay of claim 2 wherein said reaction buffered aqueous medium comprises phosphate buffered saline, pH 7.2.
Claim 7
Dependent Claim
24 words
The improved immunoassay of claim 2 wherein the 125 I-rubella virus antigen is adjusted to 50,000 CPM prior to addition to said reaction mixture.
References Cited (Backward Citations)
US4059491A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-12-10 | 1983-06-11 | 1983-12-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-12-10 | 1987-06-11 | 1987-12-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-12-10 | 1991-06-11 | 1991-12-11 | $7700.00 | Window Closed / Lapsed |